AM22, a novel synthetic microRNA, inhibits the proliferation of colorectal cancer cells by targeting core binding factor subunit β (CBFB) Fanyi MengJiawei LiWeipeng Wang PRECLINICAL STUDIES 05 January 2022 Pages: 469 - 477
Radiosensitizing effect of galunisertib, a TGF-ß receptor I inhibitor, on head and neck squamous cell carcinoma in vitro Bernhard J. JankTeresa LenzKarin Macfelda PRECLINICAL STUDIES Open access 05 January 2022 Pages: 478 - 486
IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis Xing LvQi ZhaoTao Yang PRECLINICAL STUDIES 12 January 2022 Pages: 487 - 496
Biological evaluation of complexes of cyclopentadienyl M(CO)3+ (M = Re, 99mTc) with high blood–brain barrier penetration potential as brain cancer agents B. MavroidiA. KaminariM. Pelecanou PRECLINICAL STUDIES 13 January 2022 Pages: 497 - 505
Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells Lu WangDan HuLin Xie PRECLINICAL STUDIES Open access 28 January 2022 Pages: 506 - 518
Investigation of the effects of the toll-like receptor 4 pathway on immune checkpoint vista in pancreatic cancer Kubra Sena Bas TopcuEmine Nedime KorucuTugce Duran PRECLINICAL STUDIES 03 February 2022 Pages: 519 - 528
The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma Chang-Won KangKatherine M. HannanLucy A. Coupland PRECLINICAL STUDIES Open access 24 February 2022 Pages: 529 - 536
IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4 Jia HuoLijun FuMingzhi Zhang PRECLINICAL STUDIES 28 February 2022 Pages: 537 - 545
Actively targeted delivery of SN38 by ultrafine iron oxide nanoparticle for treating pancreatic cancer Ting XuePeijia XuLiya Wang PRECLINICAL STUDIES 15 March 2022 Pages: 546 - 555
The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells Alice NicolaiSamanta TauroneSusanna Scarpa PRECLINICAL STUDIES Open access 21 March 2022 Pages: 556 - 564
Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cells Marcela MárquezKarl Holmberg OlaussonAnders R. Holmberg PRECLINICAL STUDIES Open access 21 March 2022 Pages: 565 - 575
Phenformin increases early hematopoietic progenitors in the Jak2V617F murine model Antônio Bruno Alves-SilvaBruna Alves FenerichFabiola Traina PRECLINICAL TRIALS 11 January 2022 Pages: 576 - 585
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies Jordan BerlinAnthony W. TolcherAmita Patnaik PHASE I STUDIES 03 February 2022 Pages: 586 - 595
Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors Saiama N. WaqarClifford RobinsonJordan Berlin PHASE I STUDIES Open access 12 February 2022 Pages: 596 - 605
A pharmacokinetic study to comparatively evaluate the bioequivalence and safety of a humanized recombinant monoclonal antibody targeting human epidermal growth factor receptor-2 with the reference Herceptin in healthy Chinese subjects Fangfang DingJie HuangGuoping Yang PHASE I STUDIES 21 February 2022 Pages: 606 - 613
An exploration of trifluridine/tipiracil in combination with irinotecan in patients with pretreated advanced gastric cancer Takuro MizukamiKeiko MinashiTakako Eguchi Nakajima PHASE I STUDIES 12 March 2022 Pages: 614 - 621
Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma Steven F. PowellMiroslaw MazurczakWilliam C. Spanos PHASE II STUDIES 21 March 2022 Pages: 622 - 633
Efficacy and safety of ramucirumab and docetaxel in previously treated patients with squamous cell lung cancer: a multicenter retrospective cohort study Hayato KawachiMotohiro TamiyaToru Kumagai PHASE III STUDIES 13 January 2022 Pages: 634 - 642
Real-world data of off-label drug use in patients with actionable genomic alterations on next-generation sequencing Gabriel Roman SouzaAhmed AbdallaDaruka Mahadevan Short Report 17 January 2022 Pages: 643 - 649
Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective study Jing-Jing WuWen-Hua WangMing-Zhi Zhang Short Report 09 February 2022 Pages: 650 - 659
The 45-month therapy outcomes of permanent seed implantation and radical prostatectomy for prostate cancer patients Chao LiMengdong ZhangXiaodong Zhang SHORT REPORT Open access 12 February 2022 Pages: 660 - 667
The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysis Stefania KokkaliIoannis KotsantisAlexandros Ardavanis SHORT REPORT 21 March 2022 Pages: 668 - 675
Author Correction: Increased DKC1 expression in glioma and its significance in tumor cell proliferation, migration and invasion Fa-an MiaoKun ChuYong-ping You Author Correction 10 January 2022 Pages: 676 - 678
Author Correction: Phase I trial of ATM inhibitor M3541 in combination with palliative radiotherapy in patients with solid tumors Saiama N. WaqarClifford RobinsonJordan Berlin Author Correction Open access 28 February 2022 Pages: 679 - 679
